Results 121 to 130 of about 18,181 (226)

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

open access: yesDrug Design, Development and Therapy, 2017
Martin Schiestl,1 Markus Zabransky,2 Fritz Sörgel3,4 1Sandoz GmbH, Kundl, Austria; 2Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany; 3Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany; 4Institute of ...
Schiestl M, Zabransky M, Sörgel F
doaj  

Literature review of international biosimilar medicines

open access: yes, 2016
This report provides an update to the comprehensive literature search previously conducted on behalf of the Department of Health. To inform the activities related to GBMA Education's Biosimilar Education Grant these reviews examine all international and ...
Ward, M., Staff, K., Reuter Lange, S.
core  

Adverse events reported in trials comparing biosimilar and reference insulins.

open access: yes, 2018
Adverse events reported in trials comparing biosimilar and reference insulins.
Carolyn Tieu (5117252)   +4 more
core   +1 more source

Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review

open access: yesEndocrinology, Diabetes & Metabolism
Background The option to switch patients to more cost‐effective biosimilar insulins has been available since 2014, and the market share for these medicines has been slowly increasing since then. This scoping review aimed to identify the current knowledge
Ben Hindley   +4 more
doaj   +1 more source

Patent and Regulatory Landscape of Biosimilars in the United States and Europe: Implications for Advancing the Domestic Biosimilar Industry with a Focus on Anti-TNF-α Biopharmaceuticals

open access: yesJournal of Intellectual Property
Biopharmaceuticals exhibit excellent therapeutic efficacy; however, their high cost remains a significant limitation. The introduction of biosimilars is expected to enhance market competition and reduce biopharmaceutical prices.
Tae-Kwon Kim, Tai-Hyun Kang
doaj   +1 more source

Focus on biosimilar etanercept – bioequivalence and interchangeability

open access: yes, 2018
Fabrizio Cantini,1 Maurizio Benucci2 1Department of Rheumatology, Hospital of Prato, Prato, Italy; 2Rheumatology Unit, Hospital S. Giovanni di Dio, Florence, Italy Background: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015 ...
Cantini F, Benucci M
core  

Clinical Comparison of Renogen, a Biosimilar Epoetin-a, with the Originator, Eprex, in Chronic Kidney Disease Anemia in Indonesia: A Preliminary Study

open access: yesActa Medica Indonesiana, 2019
Background: treatment of erythropoietin (EPO) is essential in chronic kidney disease (CKD) patients to maintain optimal hemoglobin (Hb) level. Renogen is a biosimilar epoetin-α, and Eprex is the originator epoetin-α.
Ni Made Hustrini   +3 more
doaj  

Literature review of international biosimilar medicines: update March - May 2018

open access: yes, 2018
This report provides an update to the comprehensive literature search previously conducted on behalf of the Department of Health. To inform the activities related to GBMA Education's Biosimilar Education Grant these reviews examine all international and ...
Ward, M., Staff, K., Reuter Lange, S.
core  

Home - About - Disclaimer - Privacy